BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Small Cell Lung Cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Prognosis
590 results:

  • 1. [Clinical characteristics and prognosis analysis of pulmonary sarcomatoid carcinoma].
    Feng XY; Chen MJ; Xu Y; Zhong W; Liu XY; Gao XX; Zhao J; Wang MZ
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):319-324. PubMed ID: 38599806
    [No Abstract]    [Full Text] [Related]  

  • 2. Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer.
    Bi YY; Chen Q; Yang MY; Xing L; Jiang HL
    Nat Commun; 2024 Mar; 15(1):2759. PubMed ID: 38553451
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The interplay between autophagy and apoptosis: its implication in lung cancer and therapeutics.
    Biswas U; Roy R; Ghosh S; Chakrabarti G
    Cancer Lett; 2024 Mar; 585():216662. PubMed ID: 38309614
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
    Liu S; Chai T; Garcia-Marques F; Yin Q; Hsu EC; Shen M; Shaw Toland AM; Bermudez A; Hartono AB; Massey CF; Lee CS; Zheng L; Baron M; Denning CJ; Aslan M; Nguyen HM; Nolley R; Zoubeidi A; Das M; Kunder CA; Howitt BE; Soh HT; Weissman IL; Liss MA; Chin AI; Brooks JD; Corey E; Pitteri SJ; Huang J; Stoyanova T
    Cell Rep Med; 2024 Feb; 5(2):101381. PubMed ID: 38244540
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Non-invasive decision support for clinical treatment of non-small cell lung cancer using a multiscale radiomics approach.
    Zhang X; Zhang G; Qiu X; Yin J; Tan W; Yin X; Yang H; Wang H; Zhang Y
    Radiother Oncol; 2024 Feb; 191():110082. PubMed ID: 38195018
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer.
    Wang L; Diao M; Zhang Z; Jiang M; Chen S; Zhao D; Liu Z; Zhou C
    Lung Cancer; 2024 Jan; 187():107439. PubMed ID: 38113653
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. The interaction of mast cells with membranes from lung cancer cells induces the release of extracellular vesicles with a unique miRNA signature.
    Shemesh R; Laufer-Geva S; Gorzalczany Y; Anoze A; Sagi-Eisenberg R; Peled N; Roisman LC
    Sci Rep; 2023 Dec; 13(1):21544. PubMed ID: 38057448
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Exploring the lncRNA-VEGF axis: Implications for cancer detection and therapy.
    Alharthi NS; Al-Zahrani MH; Hazazi A; Alhuthali HM; Gharib AF; Alzahrani S; Altalhi W; Almalki WH; Khan FR
    Pathol Res Pract; 2024 Jan; 253():154998. PubMed ID: 38056133
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The enrichment of Fanconi anemia/homologous recombination pathway aberrations in ATM/ATR-mutated NSCLC was accompanied by unique molecular features and poor prognosis.
    Wei W; Shi F; Xu Y; Jiao Y; Zhang Y; Ou Q; Wu X; Yang L; Lai J
    J Transl Med; 2023 Dec; 21(1):874. PubMed ID: 38041093
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Association of TOP2A and ADH1B with lipid levels and prognosis in patients with lung adenocarcinoma and squamous cell carcinoma.
    Yin D; Zhang Y; Li H; Cheng L
    Clin Respir J; 2023 Dec; 17(12):1301-1315. PubMed ID: 37985446
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. ARID3A and ARID3B exert direct regulatory control over the long non-coding RNAs (lncRNAs) MALAT1 and NORAD within the context of non-small cell lung cancer (NSCLC).
    Nasuh S; Balci SO; Bozgeyik I; Ikeda MA; Tekayev M; Saadat KASM
    Pathol Res Pract; 2023 Dec; 252():154948. PubMed ID: 37977034
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Overexpression of PSAT1 is Correlated with Poor prognosis and Immune Infiltration in Non-small cell lung cancer.
    Li H; Wu C; Chang W; Zhong L; Gao W; Zeng M; Wen Z; Mai S; Chen Y
    Front Biosci (Landmark Ed); 2023 Oct; 28(10):243. PubMed ID: 37919070
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases.
    Bai K; Chen X; Qi X; Zhang Y; Zou Y; Li J; Yu L; Li Y; Jiang J; Yang Y; Liu Y; Feng S; Bu H
    J Neurooncol; 2023 Oct; 165(1):149-160. PubMed ID: 37897649
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Clinical significance of tp53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update.
    Moes-Sosnowska J; Szpechcinski A; Chorostowska-Wynimko J
    Tumour Biol; 2024; 46(s1):S309-S325. PubMed ID: 37840519
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The prognostic impact of KRAS, tp53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
    Proulx-Rocray F; Routy B; Nassabein R; Belkaid W; Tran-Thanh D; Malo J; Tonneau M; Ouarzadi OE; Florescu M; Tehfe M; Blais N
    Cancer Treat Res Commun; 2023; 37():100767. PubMed ID: 37832364
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Implication of cytoplasmic p53 expression in pulmonary neuroendocrine carcinoma using next-generation sequencing analysis.
    Jimbo N; Ohbayashi C; Fujii T; Takeda M; Mitsui S; Tsukamoto R; Tanaka Y; Itoh T; Maniwa Y
    Histopathology; 2024 Jan; 84(2):336-342. PubMed ID: 37814580
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The XRCC1 and tp53 gene polymorphisms are associated with advanced-stage disease and early distant metastasis at diagnosis in non-small cell lung cancer.
    Karaağaç M; Geredeli Ç; Yıldırım MS; Altınok T; Dede İ; İnal A; Zamani AG; Kaya B; Demirkazık A; Artaç M
    J Cancer Res Ther; 2023; 19(5):1248-1254. PubMed ID: 37787291
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Network module analysis and molecular docking-based study on the mechanism of astragali radix against non-small cell lung cancer.
    Xiao W; Xu Y; Baak JP; Dai J; Jing L; Zhu H; Gan Y; Zheng S
    BMC Complement Med Ther; 2023 Sep; 23(1):345. PubMed ID: 37770919
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. The possibility of mutations of RAS signaling genes and/or tp53 in combination as a negative prognostic impact on pathological stage I non-small cell lung cancer.
    Honda T; Seto K; Endo S; Takemoto A; Tanimoto K; Kobayashi M; Kitano M; Sakakibara R; Mitsumura T; Ishibashi H; Inazawa J; Tanaka T; Miyazaki Y; Okubo K
    Cancer Med; 2023 Oct; 12(19):19406-19413. PubMed ID: 37712717
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers.
    Quintanal-Villalonga A; Durani V; Sabet A; Redin E; Kawasaki K; Shafer M; Karthaus WR; Zaidi S; Zhan YA; Manoj P; Sridhar H; Shah NS; Chow A; Bhanot UK; Linkov I; Asher M; Yu HA; Qiu J; de Stanchina E; Patel RA; Morrissey C; Haffner MC; Koche RP; Sawyers CL; Rudin CM
    Sci Transl Med; 2023 Aug; 15(707):eadf7006. PubMed ID: 37531417
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 30.